US 4,925,672 AGrant
Products Containing a Calcium Antagonist and a Lipid-Lowering Agent
Issue Date:1990-05-15
•7 Claims
Abstract
Combinations of calcium antagonists and lipid-lowering agents are suitable for controlling diseases.
Metadata
Assignee
- Knoll AG
Inventors
- Dorothee Gremm
- Ingetraud Perstel
Application Information
Application Number:US 3188256
Filing Date:1989-03-06
Priority Date:1988-03-10
Art Unit:158
Classifications
IPC:
A61K 948
Field of Search:
424514470;469;451;489;457;459;456;499;501523
Patent Drawings
This patent does not have any drawings.
Description
It is known that calcium antagonists are effective drugs for the treatment of coronary heart disease (H. Eichstadt, Calcium-Antagonisten, Chapter 33 in Handbuch der inneren Medizin, Volume IX/3: Koronarerkrankungen, Editor H. Roskamm, Springer-Verlag, Berlin, 1984; U. Borchard, Spektrum Koronartherapeutika, Aesopus Verlag, Zug, 1985).
Furthermore, a number of lipid-lowering agents which can be used for the treatment of hyperlipidemia have been described (W. Kruse et al., Spektrum Lipidsenker, Aesopus Verlag, Zug, 1985). It is also known that fibrates improve the flow properties of the blood (eg. Ernst/Matrai, Therapiewoche 38 (1988), 136-139; Lecture by Leschke at the experts' discussion Aktueller Stand der Therapie von Fettstoffwechselstorungen, Wiesbaden, Oct. 10 1987; Arzte-Zeitung 6 (1987), 29).
We have found that the action of calcium antagonists can be improved by adding lipid-lowering agents.
The present invention relates to products containing a calcium antagonist and a lipid-lowering agent.
The products may be in the form of combination preparations for simultaneous use in a fixed combination or as separate components for use simultaneously or sequentially.
Particular examples of calcium antagonists are diltiazem, etafenone, fendiline, gallopamil, nifedipine, prenylamine, perhexiline and verapamil. Among these, verapamil and gallopamil are preferred.
Examples of suitable lipid-lowering agents are bezafibrate, clofibrate and aluminum clofibrate and etofylline clofibrate, colestipol, colestyramine, dextrothyroxine, etiroxate, etofibrate, fenofibrate, gemfibrozil, inositol nicotinate, magnesium pyridoxal 5'-phosphate glutamate, probucol, 3-pyridylmethanol, .beta.-sitosterol and xantinol nicotinate. Among these substances, the fibrates (benzafibrate, clofibrate, etofibrate and fenofibrate) are preferred.
If the substances contain basic groups, they can also be used for the combination preparation in the form of their salts with physiologically tolerated acids. Suitable and preferred physiologically tolerated acids are hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, malonic acid, salicylic acid, maleic acid, fumaric acid, succinic acid, ascorbic acid, malic acid, methanesulfonic acid, lactic acid, gluconic acid, glucuronic acid, amidosulfonic acid, benzoic acid and tartaric acid.
The calcium antagonist and lipid-lowering agent are present in the mixture in amounts which are at the lower limit of the doses usually recommended for these substances, or somewhat below this limit. As a rule, the ratio of the amounts of lipid-lowering agent to calcium antagonist is from 10:1 to 1:10. For a combination of verapamil and fenofibrate, this ratio is preferably from 1:2 to 2:1.
The novel combination improves the flow properties of the blood in an unexpected synergistic manner compared with the individual components of the combination. It is therefore suitable for the therapy and prevention of symptoms due to disturbances of myocardial blood flow in coronary heat disease, ie. all angina pectoris forms, for the aftertreatment of myocardial infarction and for use before and after balloon angioplasty and bypass operations.
The novel products can be administered parenterally but are preferably administered orally. Tablets, coated tablets and capsules are particularly suitable for oral administration. Sustained-release forms are especially suitable. The known processes, as described in, for example, H. Sucker et al., Pharmazeutische Technologie, Thieme-Verlag, Stuttgart 1978, are suitable for the preparation of the stated forms. It is also possible possible to convert the individual components of the mixture into administration forms and to pack these together, for example in a blister pack.
Example 1
20 Isoptin.RTM.RR sustained-release tablets and 20 Normalip.RTM. sustained-release capsules were introduced in pairs into each blister pack.
Example 2
Pellets having the following composition were prepared:
Example 3
Example 2 was repeated, except that 192.0 mg of pellets (a) and 150.3 mg of pellets (b) were introduced per hard gelatine capsule.
Example 4
Example 2 was repeated, except that 128.0 mg of pellets (a) and 300.6 mg of pellets (b) were introduced per hard gelatine capsule.
Example 5
Tablets having the following composition were compressed:
Claims
We claim:
1. A product containing the calcium antagonist verapamil and the lipid-lowering agent fenofibrate in the ratio of 10:1 to 1:10.
2. A product as claimed in claim 1, as a combination preparation for simultaneous use in a fixed combination.
3. A product as claimed in claim 1, wherein the ratio of verapamil to fenofibrate is from 1:2 to 2:1.
4. A product as claimed in claim 1, for use to treat diseases.
5. The method for treatment of disturbances of myocardial blood flow in coronary heart disease in a subject requiring such treatment which comprises administering to said subject simultaneously an effective amount of verapamil and of fenofibrate in the ratio of 10:1 to 1:10 in the form of a tablet, coated tablet or capsules.
6. The method of claim 5, wherein the ratio of the amount of administered verapamil to that of fenofibrate is 1:2 to 2:1.
7. A pharmaceutical product useful for treatment of disturbances of myocardial blood flow in coronary heart disease comprising a package containing a unit dosage as a tablet, coated tablet or capsule of verapamil copackaged in the package with a unit dosage as a tablet, coated tablet or capsule of fenofibrate, the ratio of the amount of verapamil to that of fenofibrate in the package being 10:1 to 1:10.
Patent Citations (3)
Non-Patent Literature (10)
- Bungeroth, Fortschr. Med. (DE), 1987, 105/31 (607-611).
- Furberg et al, Am. J. Med. (U.S.A.), 1984, 76/6A (76-83).
- Scrip World Pharmaceutical News, 1988, No. 1320, pp. 28-29.
- Scrip World Pharmaceutical News No. 884, pp. 6-8.
- Scrip World Pharmaceutical News No. 842, p. 2.
- Burberg, Am. J. Med., 76 (6A); 76-83, Jun. 22, 1984.
- Leisz et al., Aktuel. Neurol. (DE), 1984, 11/4 (129-133).
- Pedersen, Ugeskr. Laeg. (Denmark), 1982, 144/29 (2156-2164).
- Therapiewoche, vol. 38, pp. 136-139, 1988 (English summary only).
- Klin Worchenschr, vol. 66, Suppl. XIII, 1988.